For example, statin-user patients with lung adenocarcinoma had significant clinical benefits for improving overall survival compared with non-statin user patients only when tumors had p53 mutations, supporting the statins’ tumor inhibitory effects [92]. This evidence concerns the gene TP53 and neoplasm.